Evidence-Based Vasopressor Use in HRS/AKI: Guidelines for Managing Multiorgan Failure in Acute-on-Chronic Liver Failure (ACLF)
Evidence-Based Vasopressor Use in HRS/AKI: Guidelines for Managing Multiorgan Failure in Acute-on-Chronic Liver Failure (ACLF) is organized by National Kidney Foundation (NKF).
Available From: 6/27/2023
Available Until : 6/27/2024
Course Description:
Hepatorenal syndrome/acute kidney injury (HRS/AKI) is a common cause of renal failure that occurs in patients who have decompensating cirrhosis and acute liver injuries that lead to acute-on-chronic liver failure (ACLF). Patients with ACLF and multi-organ failure including HRS/AKI require constant monitoring and adjustments in therapy to maximize rates of organ function recovery and improve patient survival; newer professional society guidelines have provided insight on evidence-based best practices in management. This symposium will discuss current best practices in accurate differential diagnosis of HRS/AKI based on etiology; the safe and timely initiation of albumin-based volume management, the removal of diuretics and any nephrotoxic agents; the proactive use of evidence-based vasoconstrictor therapy for patients; and considerations of whole-patient management in multi-organ failure. The activity will conclude with a patient case simulation addressing some of the challenging decisions faced by nephrologists managing these patients.
Learning Objectives:
• Discuss current guidelines for the effective identification and management of multiorgan failure and complications arising from cirrhosis and ACLF
• Apply guideline-recommended vasopressor therapy for patients who meet diagnostic criteria for HRS/AKI
• Monitor patients with ACLF and HRS/AKI for treatment-emergent adverse events that may worsen prognosis
• Describe evidence-based best practices for the use of renal replacement therapies in patients with cirrhosis and AKI
Additional details will be posted as soon as information is available